TRVI vs. VNDA, CARA, PTI, PAHC, STOK, TNGX, GHRS, COGT, LBPH, and SAGE
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Vanda Pharmaceuticals (VNDA), Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), Phibro Animal Health (PAHC), Stoke Therapeutics (STOK), Tango Therapeutics (TNGX), GH Research (GHRS), Cogent Biosciences (COGT), Longboard Pharmaceuticals (LBPH), and Sage Therapeutics (SAGE). These companies are all part of the "medical" sector.
Trevi Therapeutics (NASDAQ:TRVI) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Trevi Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Vanda Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 6 articles in the media. Trevi Therapeutics' average media sentiment score of 0.90 beat Vanda Pharmaceuticals' score of 0.08 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Vanda Pharmaceuticals received 456 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Trevi Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -2.75%. Vanda Pharmaceuticals' return on equity of -0.90% beat Trevi Therapeutics' return on equity.
Trevi Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 230.74%. Given Trevi Therapeutics' higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Vanda Pharmaceuticals.
Summary
Trevi Therapeutics beats Vanda Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
